ClinicalTrials.gg
CompletedNCT00334386Updated Mar 6, 2015

Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.

A Phase 4 interventional study of Torasemide Prolonged Release (loop diuretic) and Torasemide Immediate Release (loop diuretic) in Hypertension, sponsored by Ferrer Internacional S.A.. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-03-06.

Sponsored by Ferrer Internacional S.A. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
388
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing Loop diuretics in Hypertension — 2 open to participants now, 2 under way, none of them phase 3. A drug class: Loop diuretics · Hypertension.

Enrollment
2nd of 12
388 · median 134
Started
2005
with 1 other
Phase 4
5 of 12
1 open now
Registered
2nd of 12
by date
Lead sponsor
1 of 12
Ferrer Internacional S.A.

Among the 12 studies testing Loop diuretics in Hypertension, this one is the 2nd largest by enrollment, is one of 2 that started in 2005, is one of 5 in phase 4, and was the 2nd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 12 studies testing Loop diuretics in Hypertension are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Loop diuretics

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Loop diuretics in Hypertension, or all of them as a file.
02

Study summary

Primary objective:To demonstrate the no-inferiority in efficacy of treatment with Torsemide-PR in relation to Torsemide-IR in patients with mild and/or moderate hypertension.

Secondary objectives: To evaluate the safety and tolerability of Torsemide-PR.

Read the detailed description

Torsemide is a loop diuretic from the group of pyridine-sulfonylureas, which acts on the ascending large portion of the Henle loop where it inhibits the Na+/K+/2Cl- transport!system and blocks Cl- channels.Therefore, sodium and chlorine ions and water can not be reabsorbed in the tubule and the urine volume increases significantly. Torsemide is used for the treatment of oedema associated with congestive heart failure, kidney or liver disease and, either alone or combined with other anti-hypertensive drugs, for the treatment of arterial hypertension.

This trial compares the effect of a new formulation of Torasemide (Torasemide prolonged release)to the already available immediate release formulation of the same drug on the treatment of mild to moderate hypertensive patients.

Eligible patients will be randomised to either treatment with Torasemide prolonged release or with Torasemide immediate release and will be followed-up until completing 3 months of treatment.Blood pressure will be measured by an OMRON pressure gauge. Additionally, ABPM will be performed on a sub-group of the patients taking part in this trial.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
  • Anti-hypertensive effect
  • Diuretic
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged from 18 to 75, inclusive.
  2. Ambulatory patients diagnosed with mild or moderate arterial hypertension complying with the following requirements:

    1. Patients diagnosed "de novo".
    2. Patients with prior anti-hypertensive treatment in monotherapy who do not respond to the treatment and, in the investigator's opinion, could benefit from diuretic treatment in monotherapy.
    3. Patients with prior anti-hypertensive treatment in monotherapy who do not tolerate the current treatment and, in the investigator's opinion, could benefit from diuretic treatment in monotherapy.

    Patients with prior treatment must be able to interrupt their present treatment for a period of up to 3 months.

    (Mild or moderate hypertension defined by blood pressure levels: Systolic blood pressure from 140-179 mm Hg and diastolic blood pressure from 90-109 mm Hg) (2003 European Society of Hypertension-European Society of Cardiology guidelines for management of arterial hypertension) (3)

  3. Capable of understanding the nature of the trial.
  4. Providing their in writing.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women and women of fertile age who are not using a safe method or do not intend to use one during the trial. Safe contraceptive methods are oral or parenteral contraceptive treatments or barrier methods: masculine or feminine condom, diaphragm and/or IUD.
  2. Severe arterial hypertension (systolic blood pressure of 180 mmHg or above and diastolic blood pressure of 110 mmHg or above).
  3. Known or suspected secondary arterial hypertension.
  4. History of known to the compound under study or to sulfonylureas.
  5. History of repeated and documented hypertensive crises.
  6. grade II to IV congestive heart failure.
  7. Severe cardiac arrhythmia (sustained ventricular tachycardia, auricular fibrillation, auricular flutter, bradycardia under 45 beats per minute).
  8. Unstable angina pectoris.
  9. Acute myocardial infarct in the last 6 months.
  10. Liver failure defined by the following analytical parameters: - (ALT) or SGOT (AST) over twice the upper normal limit.
  11. Chronic kidney failure defined by the following analytical parameters: Serum creatinine over 2.3 mg/dl (or 203 mol/L).
  12. Patients with insulin-dependent diabetes and patients with non-insulin dependent diabetes.
  13. Cerebrovascular accident in the last 6 months.
  14. in the data obtained during the selection process in the physical examination, haematology, biochemistry, urine analysis and 12-lead , in the investigator's opinion.
  15. Simultaneous participation in another clinical trial or treatment with any drug within the 30 days prior to signing the form.
  16. Lactose intolerance.
  17. Concomitant treatment with lithium.
  18. Patients requiring chronic treatment (treatment > 7 days) with non-steroidal anti-inflammatory drugs, including aspirin.
  19. Patients with concomitant treatment with aminoglycoside antibiotics, etacrynic acid.
  20. Chronic administration of any medication affecting blood pressure.
  21. Patients in treatment with group 1a, 1b or 2 anti-arrhythmic drugs.
  22. History of drug or alcohol addiction within the 6 months prior to the start of the trial.
  23. Any clinical circumstance or condition which, in the investigator's opinion, could affect the possibility of completing the protocol and the administration of Torasemide.
  24. Obesity with a (BMI) of over 40 kg/m2.
  25. Patients who do not respond to diuretic treatment in monotherapy.
  26. Patients with prior anti-hypertensive treatment in monotherapy who are candidates for anti-hypertensive treatment in polytherapy.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
388 participants
06

What researchers measure

Primary outcomes

  1. Difference in mm Hg between the mean diastolic blood pressure (DBP) values the baseline period and the values at the end of the treatment period.

Secondary outcomes

  1. Difference in mm Hg, systolic blood pressure (SBP) values in the baseline period and the values at the end of the treatment period.

  2. Percentage of patients with controlled blood pressure (SBP < 140 and/or DBP < 90) at the end of the treatment period.

  3. Urinary symptoms.

  4. ABPM values measured in a subgroup of patients

  5. Safety & tolerability.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2006
First posted
Jun 7, 2006
Start
Apr 2005
Completion
Feb 2006
Last update
Mar 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Mar 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00334386
First posted
Jun 7, 2006
Start date
Apr 2005
Completion
Feb 2006
Last update
Mar 6, 2015

Study contacts

Alex Roca, MD, PhD
study chair · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Antonio Coca, MD, PhD
principal investigator · H. Clínic Barcelona, Barcelona, Spain
Joaquim Vila, MD
principal investigator · Hospital Municipal de Badalona, Badalona, Barcelona, Spain
Javier Sobrino, MD
principal investigator · Hospital del Esperit Sant, Santa Coloma de Gramanet, Barcelona, Spain
Jaume Plana, MD
principal investigator · Hospital Residencia Sant Camil, Sant Pere de Ribes, Barcelona, Spain
Xavier Farres, MD
principal investigator · Centre d'Atenció Primaria El Remei de Vic, Vic, Barcelona, Spain
Joan Garcia, MD, PhD
principal investigator · Hospital Universitario La Paz
Manuel Luque, MD
principal investigator · Hospital Clínico San Carlos, Madrid, Spain
Luis De Teresa, MD
principal investigator · Hospital de Sant Vicenç de Raspeig, Sant Vicenç de Raspeig, Alicante, Spain
Jose Vicente, MD
principal investigator · Centro de Salud de Petrel, Petrel, Alicante, Spain
Angela Felip, MD, PhD
principal investigator · Hospital de Mataró, Mataró, Barcelona, Spain
Pedro Aranda, MD, PhD
principal investigator · Hospital Universitario Carlos Haya, Málaga, Spain
Pablo Gómez, MD, PhD
principal investigator · Hospital de Jerez de la Frontera, Cádiz, Spain
Blas Gil, MD
principal investigator · Hospital Clínico Universitario San Cecilio, Granada, Spain
Joaquín Aracil, MD
principal investigator · Centro de Salud El Cristo, Oviedo, Asturias, Spain
Miguel A Prieto, MD
principal investigator · Centro de Salud Vallobin Concinos, Oviedo, Asturias, Spain
Carles Brotons, MD, PhD
principal investigator · Centre d'Atenció Primaria Sardenya, Barcelona, Spain
Félix Laporta, MD
principal investigator · Centro de Salud La Roda, La Roda, Albacete, Spain
José A División, MD
principal investigator · Centro de Salud de Fuentealbilla, Fuentealbilla, Albacete, Spain
Enrique López, MD
principal investigator · Centro de Salud de Chinchilla, Chinchilla, Albacete, Spain
Carlos Calvo, MD, PhD
principal investigator · Hospital Universitario de Santiago, Santiago de Compostela, Spain
Emili Marco, MD
principal investigator · Centre d'Atenció Primaria de Sarrià de Ter, Sarrià de Ter, Girona, Spain
Joan Martorell, MD
principal investigator · Centre de Salut de Guisona, Guisona, Lleida, Spain
Montserrat Pujol, MD
principal investigator · Centre d'Atenció Primaria El Carmel, Barcelona, Spain
Raquel Adroer, MD
principal investigator · Centre d'Atenció Primaria Florida Nord, Barcelona, Spain
Angel Cano, MD
principal investigator · Centre d'Atenció Primaria Bon Pastor, Barcelona, Spain
Nadezhda S Alexeeva, PhD
principal investigator · St. Petersburg Cardiology Clinic, St. Petesburg, Russia
Andrei Y Baranovsky, MD, PhD
principal investigator · St. Petersburg City Hospital #31, St. Petesburg, Russia
Svetlana A Boldueva, MD, PhD
principal investigator · St. Petersburg Mechnikov State Medical Academy, St. Petesburg, Russia
Svetlana K Churina, MD, PhD
principal investigator · Pokrovskaya Hospital, 1-st and 2-nd Cardiology Department, St. Petesburg, Russia
Boris M Goloschekin, MD, PhD
principal investigator · St. Petersburg City Hospital #15, St. Petesburg, Russia
Yanis Y Dumpis, MD
principal investigator · St.Petersburg Mechnikov State Medical Academy North-West Center of Arrhythmia Diagnostics and Treatment, St. Petesburg, Russia
Konstantin N Zrazhevsky, MD, PhD
principal investigator · St.Petersburg City Hospital #8, St. Petesburg, Russia
Victor Kostenko, MD, PhD
principal investigator · St.Petersburg City Outpatient Unit #109, St. Petesburg, Russia
Elena F Pavlysh, MD, PhD
principal investigator · St.Petersburg City Outpatient Unit #25, St. Petesburg, Russia
Lev A Sorokin, MD, PhD
principal investigator · St. Elizabeth City Hospital, St. Petesburg, Russia
Irina A Zobenko, MD
principal investigator · JSC Chernaya Rechka Health Center, St. Petesburg, Russia
Alexander O Sherenkov, MD, PhD
principal investigator · Krasnogvardeysky District Medical-Physiology Clinic, St. Petesburg, Russia
Alexander V Orlov-Morozov, MD, PhD
principal investigator · Moscow City Hospital #23, Moscow, Russia
Vladimir A Parfenov, MD, PhD
principal investigator · Moscow City Hospital #61, Moscow, Russia
Victor A Milyagin, MD, PhD
principal investigator · Smolensk State Medical Academy, Smolensk, Russia
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Loop diuretics

Start the discussion